started · updated
Elisigen wins Bayer Co. Lab Connect Seoul biotech program
Elisigen, a South Korean biotechnology startup specializing in Adeno-associated virus (AAV) based gene therapies, has been named the winner of the Bayer Co. Lab Connect Seoul program. The open innovation initiative, launched by Bayer Korea, aimed to discover and support early-stage domestic biotech companies in fields such as precision oncology, immunology, and AI-driven drug discovery.
Out of approximately 40 applicants, Elisigen emerged as the final winner following a rigorous evaluation process involving mentoring workshops and deep assessments by experts from Bayer and the Korea Drug Development Fund (KDDF). The company was recognized for its technological potential in treating ocular diseases, specifically through its EG103 pipeline, which targets geographic atrophy in late-stage dry age-related macular degeneration (dAMD).
As the winner, Elisigen will receive one year of intensive support, including customized mentoring from Bayer’s global R&D and business development experts, access to Bayer’s global network, and opportunities to connect with international investors. The company also highlighted its main pipeline, NG101, which is currently undergoing Phase 1/2a clinical trials in the United States and Canada.
Entities
Bayer Korea · Elisigen · Kim Jong-muk · Korea Drug Development Fund · Lee Jin-ah
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Elisigen will receive one year of mentoring and global networking support from Bayer experts. www.bosa.co.kr · www.thebionews.net · www.bokuennews.com
- [○ 1 SOURCE] The NG101 pipeline is currently undergoing Phase 1/2a clinical trials in the US and Canada. www.thebionews.net
- [● 3 SOURCES] Bayer Korea selected Elisigen as the winner of the Bayer Co. Lab Connect Seoul program. www.bosa.co.kr · www.thebionews.net · www.bokuennews.com
- [● 3 SOURCES] Approximately 40 biotech companies applied to the program. www.bosa.co.kr · www.thebionews.net · www.bokuennews.com
- [● 3 SOURCES] The company's EG103 pipeline targets geographic atrophy in late-stage dry age-related macular degeneration. www.bosa.co.kr · www.thebionews.net · www.bokuennews.com